06996.HK
Antengene Corporation Limited
HKSE · Healthcare · Biotechnology · CN
HKD 3.31
+1.85%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 3.50
From 52W high−57.18%
Volume948500.00
Market capHKD 2.07B
P/E (TTM)35.4x
P/S (TTM)3.2x
Div yield—
Key dataSep 18, 2026
Open
HKD 3.50
From 52W high
−57.18%
Volume
948500.00
Market cap
HKD 2.07B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
7.3x
P/E (TTM)
35.4x
RSI (14)
35.0
MomentumView details →
1D Return
+1.85%
YTD Return
−12.66%
Similar companies
Latest newsMore news →
Antengene announced that its Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell related autoimmune diseases, received approval from the Australian Human Research Ethics Committee and completed the Clinical Trial Notification submission to the Therapeutic Goods Administration.27d agoAntengene Corporation reported interim results for the six months ended June 30, 2026, with revenue of RMB 513 million, up 865% year-over-year, and a net profit of RMB 216 million, reversing a loss of RMB 76.378 million in the prior-year period.30d ago